GLP-1 Drugs and Medicare's Drug Price Negotiation Program
Medicare's negotiation authority under federal law applies to a rotating list of high-spend drugs. Here's how GLP-1 drugs fit into that process.
By the GLP Semaglutide editorial team · Last updated August 18, 2025
Federal law created a process for Medicare to directly negotiate prices for a limited, rotating list of high-spending drugs covered under Medicare Part D, with selected drugs and negotiated prices phased in over several years.
Eligibility criteria matter
Selection for negotiation depends on total Medicare spending and the time since FDA approval, among other statutory criteria, which is why not every high-profile drug — including specific GLP-1 products — is necessarily on an early negotiation list.
Check CMS directly
CMS publishes the official list of selected drugs and negotiated prices as they're finalized. This is a legally and politically active area, and secondary coverage can lag or oversimplify the current statutory status.
Primary sources